Published in J Virol on June 01, 1991
Foot-and-mouth disease. Clin Microbiol Rev (2004) 4.34
Encapsidation of genetically engineered poliovirus minireplicons which express human immunodeficiency virus type 1 Gag and Pol proteins upon infection. J Virol (1993) 1.32
Attenuated poliovirus strain as a live vector: expression of regions of rotavirus outer capsid protein VP7 by using recombinant Sabin 3 viruses. J Virol (1994) 1.31
Complementation of a poliovirus defective genome by a recombinant vaccinia virus which provides poliovirus P1 capsid precursor in trans. J Virol (1993) 1.15
Poliovirus chimeras expressing sequences from the principal neutralization domain of human immunodeficiency virus type 1. J Virol (1992) 1.11
Vaccines prepared from chimeras of foot-and-mouth disease virus (FMDV) induce neutralizing antibodies and protective immunity to multiple serotypes of FMDV. J Virol (1994) 1.02
Use of random systematic mutagenesis to generate viable human rhinovirus 14 chimeras displaying human immunodeficiency virus type 1 V3 loop sequences. J Virol (1994) 0.98
Release of virus-like particles from cells infected with poliovirus replicons which express human immunodeficiency virus type 1 Gag. J Virol (1996) 0.91
Immunogenicity of an aphthovirus chimera of the glycoprotein of vesicular stomatitis virus. J Virol (1996) 0.77
Recombinant Encephalomyocarditis Viruses Elicit Neutralizing Antibodies against PRRSV and CSFV in Mice. PLoS One (2015) 0.76
Identification of H-2d restricted T cell epitope of foot-and-mouth disease virus structural protein VP1. Virol J (2011) 0.76
DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A (1977) 790.54
Structure of a human common cold virus and functional relationship to other picornaviruses. Nature (1985) 12.90
Three-dimensional structure of poliovirus at 2.9 A resolution. Science (1985) 11.47
Synthesis of infectious poliovirus RNA by purified T7 RNA polymerase. Proc Natl Acad Sci U S A (1986) 8.59
3'-terminal nucleotide sequence of encephalomyocarditis virus RNA determined by reverse transcriptase and chain-terminating inhibitors. Proc Natl Acad Sci U S A (1978) 6.67
The three-dimensional structure of foot-and-mouth disease virus at 2.9 A resolution. Nature (1989) 5.87
Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence. Nature (1982) 5.50
The atomic structure of Mengo virus at 3.0 A resolution. Science (1987) 4.34
Geographic distribution of wild poliovirus type 1 genotypes. Virology (1987) 4.03
Location and primary structure of a major antigenic site for poliovirus neutralization. Nature (1983) 3.64
Use of monoclonal antibodies to identify four neutralization immunogens on a common cold picornavirus, human rhinovirus 14. J Virol (1986) 3.59
The cell attachment site on foot-and-mouth disease virus includes the amino acid sequence RGD (arginine-glycine-aspartic acid). J Gen Virol (1989) 3.53
Antigenic structure of polioviruses of serotypes 1, 2 and 3. J Gen Virol (1986) 3.50
Antibodies against a preselected peptide recognize and neutralize foot and mouth disease virus. EMBO J (1982) 3.32
Poliovirus host range is determined by a short amino acid sequence in neutralization antigenic site I. Science (1988) 3.03
An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies. Nature (1989) 3.01
Engineering a poliovirus type 2 antigenic site on a type 1 capsid results in a chimaeric virus which is neurovirulent for mice. EMBO J (1988) 2.84
Location and characterization of the antigenic portion of the FMDV immunizing protein. J Gen Virol (1982) 2.62
Chemical basis of antigenic variation in foot-and-mouth disease virus. Nature (1984) 2.52
Antigen chimaeras of poliovirus as potential new vaccines. Nature (1988) 2.38
Antigenic structure of picornaviruses. Curr Top Microbiol Immunol (1990) 2.31
Poliovirus type 1/type 3 antigenic hybrid virus constructed in vitro elicits type 1 and type 3 neutralizing antibodies in rabbits and monkeys. Proc Natl Acad Sci U S A (1988) 2.07
Structural and serological evidence for a novel mechanism of antigenic variation in foot-and-mouth disease virus. Nature (1990) 1.86
Conservation in vivo of protease cleavage sites in antigenic sites of poliovirus. J Gen Virol (1987) 1.76
Analysis of neutralizing antigenic sites on the surface of type A12 foot-and-mouth disease virus. J Virol (1989) 1.59
Neutralization of foot-and-mouth disease virus can be mediated through any of at least three separate antigenic sites. J Gen Virol (1987) 1.53
Antigenic sites on foot-and-mouth disease virus type A10. J Virol (1988) 1.48
The complete nucleotide sequence of a bovine enterovirus. J Gen Virol (1988) 1.45
Analysis of neutralizing epitopes on foot-and-mouth disease virus. J Virol (1988) 1.32
An antigen chimera of poliovirus induces antibodies against human papillomavirus type 16. J Virol (1990) 1.27
Construction of a poliovirus type 1/type 2 antigenic hybrid by manipulation of neutralization antigenic site II. J Virol (1989) 1.19
Neutralizing epitopes of type O foot-and-mouth disease virus. I. Identification and characterization of three functionally independent, conformational sites. J Gen Virol (1989) 1.17
N-AgIB of poliovirus type 1: a discontinuous epitope formed by two loops of VP1 comprising residues 96-104 and 141-152. Virology (1989) 1.15
Neutralizing epitopes of type O foot-and-mouth disease virus. II. Mapping three conformational sites with synthetic peptide reagents. J Gen Virol (1989) 1.13
Epitopes on foot-and-mouth disease virus particles. I. Topology. Virology (1987) 1.12
Neutralization sites of type O1 foot-and-mouth disease virus defined by monoclonal antibodies and neutralization-escape virus variants. Virology (1988) 1.11
Evidence for at least four antigenic sites on type O foot-and-mouth disease virus involved in neutralization; identification by single and multiple site monoclonal antibody-resistant mutants. J Gen Virol (1989) 1.06
Antigenicity and immunogenicity of synthetic peptides of foot-and-mouth disease virus. J Gen Virol (1987) 1.06
A cassette vector for the construction of antigen chimaeras of poliovirus. J Gen Virol (1989) 0.98
The main antigenic determinant detected by neutralizing monoclonal antibodies on the intact foot-and-mouth disease virus particle is absent from isolated VPI. J Gen Virol (1983) 0.97
Alteration in antibody reactivity with foot-and-mouth disease virus (FMDV) 146S antigen before and after binding to a solid phase or complexing with specific antibody. J Immunol Methods (1985) 0.91
Serological prospects for peptide vaccines against foot-and-mouth disease virus. J Gen Virol (1989) 0.87
Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5'-cap function. Nature (1994) 9.30
Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome. Nature (1985) 6.01
New model for the secondary structure of the 5' non-coding RNA of poliovirus is supported by biochemical and genetic data that also show that RNA secondary structure is important in neurovirulence. J Mol Biol (1989) 4.09
The nucleotide sequence of poliovirus type 3 leon 12 a1b: comparison with poliovirus type 1. Nucleic Acids Res (1983) 4.06
Comparison of the complete nucleotide sequences of the genomes of the neurovirulent poliovirus P3/Leon/37 and its attenuated Sabin vaccine derivative P3/Leon 12a1b. Proc Natl Acad Sci U S A (1984) 3.98
The complete nucleotide sequence of a common cold virus: human rhinovirus 14. Nucleic Acids Res (1984) 3.85
The requirement for eukaryotic initiation factor 4A (elF4A) in translation is in direct proportion to the degree of mRNA 5' secondary structure. RNA (2001) 3.65
Location and primary structure of a major antigenic site for poliovirus neutralization. Nature (1983) 3.64
Antigenic structure of polioviruses of serotypes 1, 2 and 3. J Gen Virol (1986) 3.50
A single gene determines the host range of influenza virus. Nature (1977) 3.43
Identification of a cis-acting replication element within the poliovirus coding region. J Virol (2000) 3.03
An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies. Nature (1989) 3.01
The complete nucleotide sequence of coxsackievirus B4 and its comparison to other members of the Picornaviridae. J Gen Virol (1987) 3.01
Critical role of an eight-amino acid sequence of VP1 in neutralization of poliovirus type 3. Nature (1983) 2.51
Activation of the translational suppressor 4E-BP1 following infection with encephalomyocarditis virus and poliovirus. Proc Natl Acad Sci U S A (1996) 2.47
Monoclonal antibodies which block cellular receptors of poliovirus. Virus Res (1984) 2.40
Antigen chimaeras of poliovirus as potential new vaccines. Nature (1988) 2.38
A mouse model for poliovirus neurovirulence identifies mutations that attenuate the virus for humans. J Virol (1987) 2.36
The smallest genome RNA segment of influenza virus contains two genes that may overlap. Proc Natl Acad Sci U S A (1979) 2.32
The 5'-untranslated regions of picornavirus RNAs contain independent functional domains essential for RNA replication and translation. J Virol (1994) 2.32
Analysis of the c-myc IRES; a potential role for cell-type specific trans-acting factors and the nuclear compartment. Nucleic Acids Res (2000) 2.22
A poliovirus replicon containing the chloramphenicol acetyltransferase gene can be used to study the replication and encapsidation of poliovirus RNA. J Virol (1992) 2.20
Translation of encephalomyocarditis virus RNA: parameters influencing the selection of the internal initiation site. EMBO J (1994) 2.08
The two species of the foot-and-mouth disease virus leader protein, expressed individually, exhibit the same activities. Virology (1993) 2.05
Translation deficiency of the Sabin type 3 poliovirus genome: association with an attenuating mutation C472----U. Virology (1990) 2.03
A partial view of the mechanism of insulin action. Diabetologia (1981) 1.98
The 3' untranslated region of picornavirus RNA: features required for efficient genome replication. J Virol (1995) 1.96
Further mapping of markers around the centromere of human chromosome 19. Genomics (1987) 1.84
Synthesis of immunogenic, but non-infectious, poliovirus particles in insect cells by a baculovirus expression vector. J Gen Virol (1989) 1.77
Decay-accelerating factor CD55 is identified as the receptor for echovirus 7 using CELICS, a rapid immuno-focal cloning method. EMBO J (1994) 1.76
Principal and subsidiary antigenic sites of VP1 involved in the neutralization of poliovirus type 3. J Gen Virol (1985) 1.72
Reversion to neurovirulence of the live-attenuated Sabin type 3 oral poliovirus vaccine. Nucleic Acids Res (1984) 1.71
Role for poliovirus protease 2A in cap independent translation. EMBO J (1994) 1.66
Recognition of picornavirus internal ribosome entry sites within cells; influence of cellular and viral proteins. RNA (1998) 1.65
Genetic basis of attenuation of the Sabin type 2 vaccine strain of poliovirus in primates. Virology (1993) 1.64
The complete nucleotide sequence of enterovirus type 70: relationships with other members of the picornaviridae. J Gen Virol (1990) 1.64
The remaining stocks of smallpox virus should be destroyed. Science (1993) 1.62
Neutralization of foot-and-mouth disease virus can be mediated through any of at least three separate antigenic sites. J Gen Virol (1987) 1.53
A single nucleotide substitution in the internal ribosome entry site of foot-and-mouth disease virus leads to enhanced cap-independent translation in vivo. J Virol (1993) 1.50
Specificity of enzyme-substrate interactions in foot-and-mouth disease virus polyprotein processing. Virology (1989) 1.50
Nucleotide sequence of a neurovirulent variant of the type 2 oral poliovirus vaccine. J Virol (1989) 1.46
The temperature sensitivity of the Sabin type 3 vaccine strain of poliovirus: molecular and structural effects of a mutation in the capsid protein VP3. J Gen Virol (1989) 1.46
The 5' noncoding region of the type 2 poliovirus vaccine strain contains determinants of attenuation and temperature sensitivity. Virology (1991) 1.45
Poliovirus type 3: molecular cloning of the genome and nucleotide sequence of the region encoding the protease and polymerase proteins. Nucleic Acids Res (1983) 1.43
Use of a novel rapid preparation of fat-cell plasma membranes employing Percoll to investigate the effects of insulin and adrenaline on membrane protein phosphorylation within intact fat-cells. Biochem J (1980) 1.43
Construction of poliovirus intertypic recombinants by use of cDNA. J Virol (1986) 1.38
Interaction between echovirus 7 and its receptor, decay-accelerating factor (CD55): evidence for a secondary cellular factor in A-particle formation. J Virol (1997) 1.38
Correlation of RNA secondary structure and attenuation of Sabin vaccine strains of poliovirus in tissue culture. Virology (1992) 1.37
Expression of cauliflower mosaic virus gene I in insect cells using a novel polyhedrin-based baculovirus expression vector. J Gen Virol (1990) 1.35
Characterization of the echovirus 7 receptor: domains of CD55 critical for virus binding. J Virol (1995) 1.34
Cell receptors for picornaviruses as determinants of cell tropism and pathogenesis. Trends Microbiol (1998) 1.32
New poliovirus vaccines: a molecular approach. Vaccine (1984) 1.28
Viral RNA modulates the acid sensitivity of foot-and-mouth disease virus capsids. J Virol (1995) 1.27
Expression of cauliflower mosaic virus gene I using a baculovirus vector based upon the p10 gene and a novel selection method. Virology (1990) 1.27
An antigen chimera of poliovirus induces antibodies against human papillomavirus type 16. J Virol (1990) 1.27
Identification of critical amino acids within the foot-and-mouth disease virus leader protein, a cysteine protease. Virology (1995) 1.26
Target-specific arrest of mRNA translation by antisense 2'-O-alkyloligoribonucleotides. Nucleic Acids Res (1994) 1.24
Synthesis of foot-and-mouth disease virus capsid proteins in insect cells using baculovirus expression vectors. J Gen Virol (1990) 1.23
trans complementation by RNA of defective foot-and-mouth disease virus internal ribosome entry site elements. J Virol (1994) 1.23
Molecular cloning of the genomes of poliovirus type 3 strains by the cDNA: RNA hybrid method. Arch Virol (1984) 1.22
Immunization with a vaccinia recombinant expressing the F protein protects rabbits from challenge with a lethal dose of rinderpest virus. Virology (1989) 1.22
The La autoantigen contains a dimerization domain that is essential for enhancing translation. Mol Cell Biol (1997) 1.21
Monoclonal antibodies to the C4 region of human immunodeficiency virus type 1 gp120: use in topological analysis of a CD4 binding site. AIDS Res Hum Retroviruses (1992) 1.20
Induction by synthetic peptides of broadly reactive, type-specific neutralizing antibody to poliovirus type 3. Virology (1985) 1.19
Defective point mutants of the encephalomyocarditis virus internal ribosome entry site can be complemented in trans. Virology (1995) 1.18
Nucleic acid sequence of the region of the genome encoding capsid protein VP1 of neurovirulent and attenuated type 3 polioviruses. Eur J Biochem (1983) 1.18
Eukaryotic initiation factors 4A (eIF4A) and 4G (eIF4G) mutually interact in a 1:1 ratio in vivo. J Biol Chem (2001) 1.17
Genetic basis of attenuation of the Sabin oral poliovirus vaccines. Biologicals (1993) 1.17
An antibody to a synthetic peptide recognizes polyomavirus middle-T antigen and reveals multiple in vitro tyrosine phosphorylation sites. Mol Cell Biol (1984) 1.17
Complementation of defective picornavirus internal ribosome entry site (IRES) elements by the coexpression of fragments of the IRES. Virology (1997) 1.15
Encapsidation studies of poliovirus subgenomic replicons. J Gen Virol (1998) 1.15
Genetic recombination between two strains of fowl plague virus: construction of genetic maps. Virology (1979) 1.15
Anti-insulin receptor antibodies mimic the effects of insulin on the activities of pyruvate dehydrogenase and acetylCoA carboxylase and on specific protein phosphorylation in rat epididymal fat cells. Diabetologia (1980) 1.13
Characterization of echoviruses that bind decay accelerating factor (CD55): evidence that some haemagglutinating strains use more than one cellular receptor. J Gen Virol (1998) 1.13
Role of mutations G-480 and C-6203 in the attenuation phenotype of Sabin type 1 poliovirus. J Virol (1995) 1.12
The nucleotide sequence of a type 3 poliovirus isolated during a recent outbreak of poliomyelitis in Finland. J Gen Virol (1986) 1.11
Assembly of foot-and-mouth disease virus empty capsids synthesized by a vaccinia virus expression system. J Gen Virol (1995) 1.11
Role for beta2-microglobulin in echovirus infection of rhabdomyosarcoma cells. J Virol (1998) 1.11
The 5' untranslated region of Rhopalosiphum padi virus contains an internal ribosome entry site which functions efficiently in mammalian, plant, and insect translation systems. J Virol (2001) 1.10
ABC50 interacts with eukaryotic initiation factor 2 and associates with the ribosome in an ATP-dependent manner. J Biol Chem (2000) 1.09
Differentiating infection from vaccination in foot-and-mouth disease using a panel of recombinant, non-structural proteins in ELISA. Vaccine (1998) 1.08
Protein kinases and insulin action in fat cells. Biochem Soc Trans (1984) 1.07
dam methylation in the archaebacteria. J Gen Microbiol (1986) 1.06
Evidence for at least four antigenic sites on type O foot-and-mouth disease virus involved in neutralization; identification by single and multiple site monoclonal antibody-resistant mutants. J Gen Virol (1989) 1.06
Reversibility of the insulin-stimulated phosphorylation of ATP citrate lyase and a cytoplasmic protein of subunit Mr 22000 in adipose tissue. Biochem J (1982) 1.05
The effect of insulin and adrenaline on the phosphorylation of a 22 000-molecular weight protein within isolated fat cells; possible identification as the inhibitor-1 of the 'general phosphatase' [proceedings]. Biochem Soc Trans (1980) 1.05
Low diversity of foot-and-mouth disease serotype C virus in Kenya: evidence for probable vaccine strain re-introductions in the field. Epidemiol Infect (2010) 1.05
The 5' noncoding region and virulence of poliovirus vaccine strains. Trends Microbiol (1994) 1.05
Mapping the binding domains on decay accelerating factor (DAF) for haemagglutinating enteroviruses: implications for the evolution of a DAF-binding phenotype. J Gen Virol (1999) 1.04
Nucleotide sequence of the haemagglutinin gene of influenza virus A/England/321/77. J Gen Virol (1983) 1.04
Binding of a cellular factor to the 3' untranslated region of the RNA genomes of entero- and rhinoviruses plays a role in virus replication. J Gen Virol (1998) 1.03
Phosphorylation of the nucleoprotein of an avian influenza virus. J Gen Virol (1982) 1.03
The role of the 5' nontranslated regions of the fusion protein mRNAs of canine distemper virus and rinderpest virus. Virology (1990) 1.01
Sequence of genome segment 9 of bluetongue virus (serotype 1, South Africa) and expression analysis demonstrating that different forms of VP6 are derived from initiation of protein synthesis at two distinct sites. J Gen Virol (1992) 1.00